Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.